apremilast   Click here for help

GtoPdb Ligand ID: 7372

Synonyms: CC-10004 | Otezla®
Approved drug PDB Ligand Immunopharmacology Ligand
apremilast is an approved drug (FDA (2014), EMA (2015))
Compound class: Synthetic organic
Comment: Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor [1-2] (additional comment in [4]). It is selective for PDE4 over other PDE isozymes, but non-selective over PDE4 isoforms [5].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: apremilast

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 127.46
Molecular weight 460.13
XLogP 2
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOc1cc(ccc1OC)C(N1C(=O)c2c(C1=O)c(ccc2)NC(=O)C)CS(=O)(=O)C
Isomeric SMILES CCOc1cc(ccc1OC)[C@H](N1C(=O)c2c(C1=O)c(ccc2)NC(=O)C)CS(=O)(=O)C
InChI InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
Immunopharmacology Comments
Apremilast is an orally active pan-PDE4 inhibitor [5]. It has regulatory effects on innate immunity, principally by reducing TNF-α production from leukocytes. Apremilast also reduces nitric oxide synthase and IL-23 levels and increases IL-10 levels [3].
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriatic arthritis Disease Ontology: DOID:9008
Approved drug for PsA.